Differential sensitivities of trastuzumab (Herceptin®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors
- 1 May 2005
- journal article
- other
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 91 (2), 187-201
- https://doi.org/10.1007/s10549-004-7715-1
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- CI-1033, a pan-erbB tyrosine kinase inhibitorSeminars in Oncology, 2001
- Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancerCancer Gene Therapy, 2001
- The EGFR family and its ligands in human cancerEuropean Journal Of Cancer, 2001
- Biology of HER2 and Its Importance in Breast CancerOncology, 2001
- HER2 as a prognostic and predictive marker for breast cancerAnnals of Oncology, 2001
- The role of overexpressed HER2 in transformationAnnals of Oncology, 2001
- Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2001
- HER2/neu antisense targeting of human breast carcinomaOncogene, 2000
- Role of HER2 gene overexpression in breast carcinomaJournal of Cellular Physiology, 2000
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989